Relapsed/refractory acute leukemia

Clinical trials for Relapsed/refractory acute leukemia explained in plain language.

Never miss a new study

Get alerted when new Relapsed/refractory acute leukemia trials appear

Sign up with your email to follow new studies for Relapsed/refractory acute leukemia, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Not yet finished but already full! 1

Last-Resort drug access for leukemia patients

Disease control Expanded access (ended)

This program provides revumenib (SNDX-5613) to patients with relapsed or refractory acute leukemias who cannot join other studies and have no approved treatments. Participants take the drug orally every 12 hours. The goal is to offer a potential treatment option in a controlled s…

Matched conditions: RELAPSED/REFRACTORY ACUTE LEUKEMIA

Sponsor: Syndax Pharmaceuticals • Aim: Disease control

Last updated Jun 26, 2026 14:18 UTC

Relapsed/refractory acute leukemia

Get alerted when new Relapsed/refractory acute leukemia trials appear

Last-Resort drug access for leukemia patients